Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROKETAZINE vs LEVOPROME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.
Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.
Nausea and vomiting,Antipsychotic (off-label),Sedation (off-label)
Psychotic disorders,Schizophrenia,Acute mania,Nausea and vomiting,Intractable hiccups
25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.
25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.
Terminal elimination half-life is 15-20 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is approximately 24 hours (range 12–36 hours). Accumulation occurs with repeated dosing, requiring dose adjustment in hepatic impairment.
Hepatic via CYP2D6 and other cytochrome P450 enzymes.
Hepatic via CYP2D6, CYP3A4; active metabolites include methotrimeprazine sulfoxide, N-desmethylmethotrimeprazine.
Primarily renal excretion of metabolites; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 20% of total clearance.
Primarily renal (approx. 70% as conjugated metabolites, <1% unchanged), with biliary/fecal excretion (approx. 20%).
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
>99% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution is 20-30 L/kg, indicating extensive tissue distribution and high lipophilicity.
Approximately 7 L/kg (range 5–10 L/kg), indicating extensive tissue distribution.
Oral bioavailability is 30-40% due to extensive first-pass metabolism. IM bioavailability is approximately 70%.
Oral: 40–50% (first-pass effect); Intramuscular: 70–80%.
GFR 30-50 m L/min: reduce dose by 25%; GFR <30 m L/min: reduce dose by 50% and extend interval to every 12 hours.
Cr Cl 10-50 m L/min: Administer 75% of usual dose; Cr Cl <10 m L/min: Administer 50% of usual dose.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 25-50%; Child-Pugh Class C: Avoid use.
0.5-1 mg/kg intramuscularly every 6-8 hours; maximum 50 mg per day for children <12 years.
Children >12 years: 0.5-1 mg/kg intramuscularly every 6-8 hours; maximum 2 mg/kg/day. Not recommended for children under 12 years.
Initial dose 12.5 mg intramuscularly; maximum 50 mg per day; monitor for anticholinergic effects and sedation.
Initial dose: 12.5 to 25 mg intramuscularly; titrate cautiously due to increased sensitivity and risk of orthostatic hypotension.
Increased risk of death in elderly patients with dementia-related psychosis; not approved for dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis; risk of tardive dyskinesia; neuroleptic malignant syndrome (NMS).
May cause QT prolongation, neuroleptic malignant syndrome, tardive dyskinesia, hypotension, and increased risk of falls. Use with caution in patients with cardiovascular disease, seizures, or hepatic impairment.
Neuroleptic malignant syndrome, tardive dyskinesia, hypotension, seizures, anticholinergic effects, QT prolongation, agranulocytosis, photosensitivity, elevation of prolactin levels.
Hypersensitivity to phenothiazines, severe CNS depression, comatose states, and blood dyscrasias.
Comatose states, CNS depression, bone marrow suppression, pheochromocytoma, hypersensitivity to phenothiazines, concurrent use with high-dose CNS depressants.
Avoid grapefruit juice as it may inhibit metabolism and increase toxicity. Avoid high-tyramine foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis if used with MAOIs.
Avoid grapefruit and grapefruit juice as they may increase serum levels of methotrimeprazine. Limit caffeine intake as it may exacerbate side effects like restlessness. No specific food restrictions otherwise.
PROKETAZINE (prochlorperazine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third trimesters: Possible extrapyramidal symptoms and neonatal withdrawal in newborns after maternal use near term. Use only if benefit outweighs risk.
First trimester: Limited data; animal studies show increased fetal resorption and skeletal anomalies at high doses. Second and third trimesters: No evidence of major malformations; risk of neonatal extrapyramidal symptoms and jaundice with third-trimester use.
Prochlorperazine is excreted into human breast milk in low amounts. Milk/plasma (M/P) ratio is approximately 1.0. Potential for adverse effects in nursing infants, including sedation and extrapyramidal symptoms. Caution advised; monitor infant for drowsiness and EPS.
Levofloxacin (levoprome) is excreted in human milk; M/P ratio approximately 0.8. Avoid breastfeeding during therapy due to potential adverse effects on infant cartilage development.
Pregnancy may increase clearance of prochlorperazine due to expanded blood volume and enhanced hepatic metabolism. Dose adjustments may be needed; consider lower initial doses and titrate based on clinical response. No specific pharmacokinetic data in pregnancy; use minimum effective dose.
No dosage adjustment required based on pregnancy-related pharmacokinetic changes; however, use only if clearly needed due to theoretical risks to fetus.
Monitor for extrapyramidal symptoms, especially in elderly and pediatric patients. Proketazine may cause significant hypotension; avoid rapid IV administration. Contraindicated in patients with bone marrow suppression or severe hepatic impairment.
Levoprome (methotrimeprazine) is a phenothiazine neuroleptic with potent analgesic properties. It may cause significant hypotension, especially in elderly or hypovolemic patients; use with caution and monitor blood pressure. Extrapyramidal symptoms are less common than with typical antipsychotics but may occur. Avoid subcutaneous extravasation due to tissue irritation.
Avoid alcohol and CNS depressants as they may increase sedation.,Report any involuntary muscle movements or stiffness immediately.,Rise slowly from sitting or lying to prevent dizziness.,May cause dry mouth; use sugar-free gum or candy.,Do not discontinue abruptly without consulting prescriber.
This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Avoid alcohol and other central nervous system depressants.,Rise slowly from sitting or lying positions to prevent fainting.,Report any unusual muscle movements or stiffness to your healthcare provider.,Use sunscreen and protective clothing as this drug may increase sensitivity to sunlight.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROKETAZINE vs LEVOPROME, answered by our medical review team.
PROKETAZINE is a Phenothiazine Antipsychotic that works by Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.. LEVOPROME is a Phenothiazine Antipsychotic that works by Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROKETAZINE and LEVOPROME depend on the specific clinical indication. These are both Phenothiazine Antipsychotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROKETAZINE is: 25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.. The standard adult dose of LEVOPROME is: 25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROKETAZINE and LEVOPROME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROKETAZINE is classified as Category C. PROKETAZINE (prochlorperazine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third t. LEVOPROME is classified as Category C. First trimester: Limited data; animal studies show increased fetal resorption and skeletal anomalies at high doses. Second and third trimesters: No evidence of major malformations;. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.